Nav: Home

Experimental drug, implanted in eye, could fight glaucoma

October 14, 2016

Clarksburg, MD - An experimental drug, consisting of cells manufactured and implanted in the eye to stimulate optic nerve growth and activity, could be an entirely new way of fighting glaucoma, according to BrightFocus Foundation.

BrightFocus is helping fund a recently launched, Phase 2 [or mid-level] clinical trial designed to test the new treatment. The trial will be led by Jeffrey Goldberg, MD, PhD, chair of ophthalmology and director of the Byers Eye Institute at Stanford University. BrightFocus had previously funded Phase 1 of this trial.

"BrightFocus is proud to invest in research that may translate scientific discoveries into a new treatment for glaucoma," said BrightFocus President and CEO Stacy Haller. "We applaud Dr. Goldberg for his bold, innovative ideas and his dedication to improving sight for millions around the world."

Labeled NT-501 encapsulated cell therapy (or NT-501 ECT), the experimental glaucoma treatment consists of a capsule filled with human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF), which promotes nerve growth and activity. The capsule, implanted into the eye, releases a steady stream of those growth factors to protect the optic nerve. Subjects will be followed for two years to see if there is any change in vision.

Glaucoma, which progressively damages central version, is the number one cause of irreversible vision loss in the world. In the past, glaucoma research and treatments tended to focus on the damage caused by increased pressure inside the eye (intraocular pressure or IOP). In the innovative NT-501 ECT treatment, developed by Neurotech, the focus is on CNTF growth factors that may help the eyes' retinal ganglion cells (RGCs)--which are part of the optic nerve and carry light signals to the brain--resist damage.

Dr. Goldberg said his hypothesis is that NT-501 ECT might stop further loss of RGCs and vision (neuroprotection) or may improve existing vision (neuroenhancement), or possibly both. "It will be an enormous step forward if either of these can be demonstrated," Goldberg said. "We have no approved treatments that address the degeneration of the RGCs or their axons, so this is a huge unmet need."

The treatment has been previously tested in age-related macular degeneration and in an inherited form of macular degeneration known as retinitis pigmentosa, with no serious adverse effects to date. Being able to deliver growth factors, "directly to the eye, without significant exposure to the rest of the body, is a significant advantage of the NT-501 implant approach," Goldberg said.
For more information on this research and the clinical trial, visit

For an interview with Dr. Goldberg, see

BrightFocus Foundation funds research and promotes awareness to end glaucoma, Alzheimer's disease, and macular degeneration. The nonprofit currently manages a portfolio of more than 150 projects worldwide. For more information, visit

Contact Information

Michael Buckley, Vice President of Public Affairs
Phone: (301) 556-9370; Email:

Alice L. Kirkman, Communications and Marketing Manager
Phone: (301) 556-9349; Email:

BrightFocus Foundation

Related Glaucoma Articles:

Potential predictor of glaucoma damage identified
Researchers at Washington University School of Medicine in St. Louis have identified a biomarker that appears linked to damage to cells in the retina of the eye.
New eye test detects earliest signs of glaucoma
Researchers at University College London (UCL) and the Western Eye Hospital have developed a simple, inexpensive diagnostic tool DARC (Detection of Apoptosing Retinal Cells).
Vitamin B3 prevents glaucoma in laboratory mice
In mice genetically predisposed to glaucoma, vitamin B3 added to drinking water is effective at preventing the disease.
Stem cell secretions may protect against glaucoma
A new study in rats shows that stem cell secretions, called exosomes, appear to protect cells in the retina, the light-sensitive tissue in the back of the eye.
Zika and glaucoma linked for first time in new study
A team of researchers in Brazil and at the Yale School of Public Health has published the first report demonstrating that the Zika virus can cause glaucoma in infants who were exposed to the virus during gestation.
Experimental drug, implanted in eye, could fight glaucoma
An experimental drug, consisting of cells manufactured and implanted in the eye to stimulate optic nerve growth and activity, could be an entirely new way of fighting glaucoma, according to BrightFocus Foundation.
Study in mice suggests stem cells could ward off glaucoma
An infusion of stem cells could help restore proper drainage for fluid-clogged eyes at risk for glaucoma.
Why apnea patients are prone to suffer from glaucoma
Scientists at Hokkaido University have successfully measured the eye pressure of sleeping patients with obstructive sleep apnea syndrome for the first time, finding an unexpected correlation with glaucoma.
New eye test could detect glaucoma years earlier
UNSW Australia scientists have developed a testing protocol that identifies the blinding eye disease glaucoma four years earlier than current techniques.
Promising new compound protects neurons and vision in mice with glaucoma
Early tests of a novel compound in mice with glaucoma should come as welcome news to millions of people around the world now suffering with this leading cause of vision loss.

Related Glaucoma Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...